日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

口服 ERK1/2 抑制剂 MK-8353 的开发,用于治疗晚期实体肿瘤患者

Stergios J Moschos, Ryan J Sullivan, Wen-Jen Hwu, Ramesh K Ramanathan, Alex A Adjei, Peter C Fong, Ronnie Shapira-Frommer, Hussein A Tawbi, Joseph Rubino, Thomas S Rush 3rd, Da Zhang, Nathan R Miselis, Ahmed A Samatar, Patrick Chun, Eric H Rubin, James Schiller, Brian J Long, Priya Dayananth, Donna

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

发现一种新型 ERK 抑制剂,在 BRAF 和 MEK 抑制剂获得性耐药模型中具有活性

Erick J Morris, Sharda Jha, Clifford R Restaino, Priya Dayananth, Hugh Zhu, Alan Cooper, Donna Carr, Yongi Deng, Weihong Jin, Stuart Black, Brian Long, Jenny Liu, Edward Dinunzio, William Windsor, Rumin Zhang, Shuxia Zhao, Minilik H Angagaw, Elaine M Pinheiro, Jagdish Desai, Li Xiao, Gerald Shipps,